AJOVY® (fremanezumab) was first aimed to prevent episodic migraine in adults and Teva Pharmaceutical (TEVA, Financial) wonders if the same drug gives effective results to children with migraine.

And Teva just recently announced positive results from its Phase 3 SPACE (an acronym for Study of Preventive Ajovy in Children and Adolescents) evaluating AJOVY® for the prevention of episodic migraine in children and adolescents aged 6-17 years.

The trial demonstrated statistically significant superior efficacy compared to placebo over 12 weeks, with a favorable safety profile consistent with that observed in adults.

The study included 237 children who had been diagnosed with migraine for at least six months, with fewer than 14 headache days per month. Highlights from the data showed that fremanezumab achieved a significant reduction in monthly migraine days and monthly headache days compared to placebo2. Additionally, a higher number of children achieved a 50% response rate with fremanezumab compared to placebo.

This brings hopes to treat young patients who live with migraine, a condition with limited treatment choices for kids.

Make more informed investment decision now by visiting GuruFocus and deep dive into TEVA' performance with charts, insiders, political positions, guru insights and more!